
Manabu Fujimoto

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3861978/publications.pdf Version: 2024-02-01



MANABLI FUUMOTO

#	Article	IF	CITATIONS
1	Anti-nuclear matrix protein 2 antibody-positive inflammatory myopathies represent extensive myositis without dermatomyositis-specific rash. Rheumatology, 2022, 61, 1222-1227.	1.9	32
2	Clear Cell Carcinoma in the Oral Cavity with Three Novel Types of EWSR1-ATF1 Translocation: A Case Report. Head and Neck Pathology, 2022, 16, 560-566.	2.6	4
3	Differential Involvement of Programmed Cell Death Ligands in Skin Immune Responses. Journal of Investigative Dermatology, 2022, 142, 145-154.e8.	0.7	12
4	Distribution of hypomelanotic macules in tuberous sclerosis complex: A retrospective cohort study. Journal of the American Academy of Dermatology, 2022, 87, 237-240.	1.2	2
5	Case of antiâ€Miâ€⊋ antibodyâ€positive dermatomyositis with predictable onset before the development of muscle symptoms. Journal of Dermatology, 2022, 49, .	1.2	2
6	A phase I dose-escalation, safety/tolerability, and preliminary efficacy study of the intratumoral administration of GEN0101 in patients with advanced melanoma. Cancer Immunology, Immunotherapy, 2022, , 1.	4.2	1
7	Cell surface-expressed Ro52/IgG/HLA-DR complex is targeted by autoantibodies in patients with inflammatory myopathies. Journal of Autoimmunity, 2022, 126, 102774.	6.5	3
8	A Case of Pretibial Epidermolysis Bullosa with Novel Mutations of the COL7A1 Gene. Annals of Dermatology, 2022, 34, 81.	0.9	2
9	A rare case of folliculotropic mycosis fungoides with eosinophilic pneumonia. Journal of Cutaneous Immunology and Allergy, 2022, 5, 141-143.	0.3	1
10	Familial Michelin tire baby syndrome. Journal of Dermatology, 2022, 49, .	1.2	0
11	Panniculitis in dermatomyositis: Two cases with antitranscriptional intermediary factorâ€1 antibody as myositisâ€specific antibody and review of the literature. Journal of Cutaneous Immunology and Allergy, 2022, 5, 88-93.	0.3	2
12	Development of alopecia areata-like reactions in a patient treated with dupilumab. Allergology International, 2022, 71, 420-422.	3.3	5
13	Reliability of antinuclear matrix protein 2 antibody assays in idiopathic inflammatory myopathies is dependent on target protein properties. Journal of Dermatology, 2022, 49, 441-447.	1.2	3
14	Dermatomyositis. Neurology, 2022, 98, .	1.1	34
15	Clinical course of Japanese patients with early systemic sclerosis: A multicenter, prospective, observational study. Modern Rheumatology, 2021, 31, 162-170.	1.8	3
16	The Possible Linkage of Granzyme B-Producing Skin T Cells with the Disease Prognosis of Alopecia Areata. Journal of Investigative Dermatology, 2021, 141, 427-429.e10.	0.7	8
17	Langerhans Cells Suppress CD8+ T Cells In Situ during Mucocutaneous Acute Graft-Versus-Host Disease. Journal of Investigative Dermatology, 2021, 141, 1177-1187.e3.	0.7	4
18	Transcriptional intermediary factor 1 (TIF1) and anti-TIF1Î ³ antibody-positive dermatomyositis. Immunological Medicine, 2021, 44, 23-29.	2.6	14

#	Article	IF	CITATIONS
19	Generalized pustular psoriasis associated with systemic lupus erythematosus successfully treated with secukinumab. Journal of Dermatology, 2021, 48, e43-e44.	1.2	5
20	Pathologic Features of Anti-Mi-2 Dermatomyositis. Neurology, 2021, 96, e448-e459.	1.1	24
21	Imbalance toward TFH 1 cells playing a role in aberrant B cell differentiation in systemic sclerosis. Rheumatology, 2021, 60, 1553-1562.	1.9	14
22	IFN-γ–Stimulated Apoptotic Keratinocytes Promote Sclerodermatous Changes in Chronic Graft-Versus-Host Disease. Journal of Investigative Dermatology, 2021, 141, 1473-1481.e4.	0.7	9
23	Unilateral heliotrope rash: a warning sign for anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis. Rheumatology, 2021, 60, e134-e135.	1.9	3
24	Use of a combination of oral psoralen, ultraviolet A and interferonâ€Î³ for the treatment of mycosis fungoides during pregnancy, which probably evoked CD8 ⁺ CD30 ⁺ lymphoproliferative disorder. Journal of Dermatology, 2021, 48, e17-e18.	1.2	1
25	Interleukin-23 promotes CD103-negative Th17 in psoriatic non-lesional skin. Journal of Dermatological Science, 2021, 101, 72-74.	1.9	0
26	A case of eosinophilic pustular folliculitis presenting as papuloerythroderma of Ofujiâ€like eruption. Journal of Cutaneous Immunology and Allergy, 2021, 4, 37-38.	0.3	1
27	Effect of sirolimus gel on sweating: A pilot study. Journal of Dermatology, 2021, 48, e161-e162.	1.2	0
28	PD-1 Regulates Passive Anaphylaxis: A Possible Role of the Mast Cell Intracellular Inhibitory Signal. Allergy, Asthma and Immunology Research, 2021, 13, 819.	2.9	0
29	Successful treatment of acrodermatitis continua of hallopeau with an anti-IL-17A agent. Indian Journal of Dermatology, 2021, 66, 225.	0.3	1
30	Myxovirus resistance protein 1–expressing fatal myocarditis in a patient with anti-MDA5 antibody–positive dermatomyositis. Rheumatology, 2021, 60, e450-e452.	1.9	4
31	A rare case of multiple pyoderma gangrenosum coâ€mobilized with pseudoxanthoma elasticum. Journal of Cutaneous Immunology and Allergy, 2021, 4, 71-72.	0.3	1
32	Recessive dystrophic epidermolysis bullosa with extensive transplantation of cultured epidermal autograft product after cardiopulmonary resuscitation: A case report. Journal of Dermatology, 2021, 48, e194-e195.	1.2	2
33	Ganglioside GD3 May Suppress the Functional Activities of Benign Skin T Cells in Cutaneous T-Cell Lymphoma. Frontiers in Immunology, 2021, 12, 651048.	4.8	6
34	KEAP1 and epidermal differentiation: Psoriatic epidermis as a model. Journal of Cutaneous Immunology and Allergy, 2021, 4, 132-134.	0.3	2
35	Cutaneous Squamous Cell Carcinoma in the Age of Immunotherapy. Cancers, 2021, 13, 1148.	3.7	19
36	Keratinocyte IL-36 Receptor/MyD88 Signaling Mediates <i>Malassezia</i> -Induced IL-17–Dependent Skin Inflammation. Journal of Infectious Diseases, 2021, 223, 1753-1765.	4.0	5

#	Article	IF	CITATIONS
37	Case of hepatosplenic Tâ€cell lymphoma in a patient with dermatomyositis treated with prednisolone and azathioprine. Journal of Dermatology, 2021, 48, e275-e276.	1.2	1
38	Immune response to dermatomyositis-specific autoantigen, transcriptional intermediary factor 1Î ³ can result in experimental myositis. Annals of the Rheumatic Diseases, 2021, 80, 1201-1208.	0.9	20
39	A case of anti-PL-7 antibody-positive anti-synthetase syndrome with dermatomyositis-associated erythema induced sclerodermatous changes. Rheumatology, 2021, 60, e362-e364.	1.9	0
40	A prospective, phase II study on the safety and efficacy of negative pressure closure for the stabilization of splitâ€thickness skin graft in large or muscleâ€exposing defects: The NPSG study. Journal of Dermatology, 2021, 48, 1350-1356.	1.2	5
41	Large-scale plasma-metabolome analysis identifies potential biomarkers of psoriasis and its clinical subtypes. Journal of Dermatological Science, 2021, 102, 78-84.	1.9	15
42	Altered nucleocytoplasmic staining patterns of p62/SQSTM1 in cutaneous squamous cell carcinoma precursors. Journal of Cutaneous Immunology and Allergy, 2021, 4, 137-138.	0.3	0
43	Papulonodular lesions in Erdheim–Chester disease. Journal of Dermatology, 2021, 48, e445-e446.	1.2	1
44	Clinical characteristics of four myositis-specific autoantibodies with regulatory-approved testing in Japan: A Japanese multi-centre adult myositis patients' cohort. Journal of Dermatological Science, 2021, 103, 53-56.	1.9	1
45	A pediatric case of cellulitis caused by <i>Stenotrophomonas maltophilia</i> with subcutaneous microvascular thrombosis and diffuse hemorrhage. Journal of Cutaneous Immunology and Allergy, 2021, 4, 181-183.	0.3	Ο
46	Possible activation of effector B cells during drugâ€induced hypersensitivity syndrome. Journal of Cutaneous Immunology and Allergy, 2021, 4, 166-169.	0.3	0
47	Refractory dermatomyositis which developed in a patient with silicone breast implants. Allergology International, 2021, 71, 158-158.	3.3	1
48	Serum lactate dehydrogenase level as a possible predictor of treatment preference in psoriasis. Journal of Dermatological Science, 2021, 103, 109-115.	1.9	5
49	Dihydroartemisinin Alleviates Imiquimod-Induced Psoriasis-like Skin Lesion in Mice Involving Modulation of IL-23/Th17 Axis. Frontiers in Pharmacology, 2021, 12, 704481.	3.5	5
50	Combination Treatment of Topical Imiquimod Plus Anti-PD-1 Antibody Exerts Significantly Potent Antitumor Effect. Cancers, 2021, 13, 3948.	3.7	9
51	Skin T cells maintain their diversity and functionality in the elderly. Communications Biology, 2021, 4, 13.	4.4	14
52	Successful treatment of cheilitis granulomatosa with diaminodiphenyl sulfone. Journal of Cutaneous Immunology and Allergy, 2021, 4, 45-46.	0.3	0
53	Successful High-Dose Radiation Treatment for Chemo-Resistant Oral Squamous Cell Carcinoma in a Kindler's Syndrome Patient. Annals of Dermatology, 2021, 33, 382.	0.9	1
54	Dihydroartemisinin: A Potential Drug for the Treatment of Malignancies and Inflammatory Diseases. Frontiers in Oncology, 2021, 11, 722331.	2.8	20

#	Article	IF	CITATIONS
55	Clinical and laboratory parameters predicting cancer in dermatomyositis patients with anti-TIF1γ antibodies. Journal of Dermatological Science, 2021, 104, 177-184.	1.9	6
56	Loricrin and NRF2 Coordinate Cornification. JID Innovations, 2021, 2, 100065.	2.4	5
57	Efficacy and safety of a modified combination regimen of phenothrin and ivermectin lotion in patients with head lice in Tsukuba, Japan. Journal of Cutaneous Immunology and Allergy, 2021, 4, 4-12.	0.3	1
58	Hypohidrosis in the macules in tuberous sclerosis complex and neurofibromatosis. Journal of Dermatology, 2021, 48, 418-419.	1.2	0
59	Idiopathic inflammatory myopathies. Nature Reviews Disease Primers, 2021, 7, 86.	30.5	212
60	Loricrin Protects against Chemical Carcinogenesis. Journal of Investigative Dermatology, 2021, , .	0.7	2
61	Wound, pressure ulcer and burn guidelines – 2: Guidelines for the diagnosis and treatment of pressure ulcers, second edition. Journal of Dermatology, 2020, 47, 929-978.	1.2	7
62	Anaphylaxis caused by sodium caseinate contained in canned coffee. Allergology International, 2020, 69, 157-158.	3.3	0
63	239th ENMC International Workshop: Classification of dermatomyositis, Amsterdam, the Netherlands, 14–16 December 2018. Neuromuscular Disorders, 2020, 30, 70-92.	0.6	148
64	Fixed drug eruption caused by allylisopropylacetylurea mimicking contact dermatitis of the face. Contact Dermatitis, 2020, 82, 56-57.	1.4	2
65	A case of cold-induced cholinergic urticaria accompanied by cholinergic urticaria showing a positive ice cube test. Allergology International, 2020, 69, 150-151.	3.3	3
66	First external validation of sensitivity and specificity of the European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria for idiopathic inflammatory myopathies with a Japanese cohort. Annals of the Rheumatic Diseases, 2020, 79, 387-392.	0.9	17
67	Pregnancy triggers the onset of anti-transcriptional intermediary factor $1^{\hat{1}3}$ antibody-positive dermatomyositis: a case series. Rheumatology, 2020, 59, 1450-1451.	1.9	13
68	CD22 and CD72 contribute to the development of scleroderma in a murine model. Journal of Dermatological Science, 2020, 97, 66-76.	1.9	8
69	Characteristics of Japanese patients with eosinophilic fasciitis: A brief multicenter study. Journal of Dermatology, 2020, 47, 1391-1394.	1.2	3
70	Honey and Chamomile Activate Keratinocyte Antioxidative Responses via the KEAP1/NRF2 System. Clinical, Cosmetic and Investigational Dermatology, 2020, Volume 13, 657-660.	1.8	7
71	Activation of CD8 T cells accelerates anti-PD-1 antibody-induced psoriasis-like dermatitis through IL-6. Communications Biology, 2020, 3, 571.	4.4	31
72	NRF2 Augments Epidermal Antioxidant Defenses and Promotes Atopy. Journal of Immunology, 2020, 205, 907-914.	0.8	17

#	Article	IF	CITATIONS
73	Case of Xâ€linked hypohidrotic ectodermal dysplasia, along with facial bilateral reticular pigmentation. Journal of Cutaneous Immunology and Allergy, 2020, 3, 41-42.	0.3	0
74	A case of drugâ€induced hypersensitivity syndrome due to diaminodiphenyl sulfone complicated by acute respiratory failure with atypical erythema around existing prurigo. Journal of Cutaneous Immunology and Allergy, 2020, 3, 45-47.	0.3	1
75	A case of antiâ€NXPâ€2â€positive dermatomyositis with generalized subcutaneous edema. Journal of Cutaneous Immunology and Allergy, 2020, 3, 115-116.	0.3	1
76	Achievement of remission with surgical resection of a lung adenocarcinoma without systemic treatment in a rare case of antiâ€IIF1â€Î³ antibodyâ€positive dermatomyositis. Journal of Cutaneous Immunology and Allergy, 2020, 3, 117-119.	0.3	1
77	Dihydroartemisinin inhibits melanoma by regulating CTL/Treg anti-tumor immunity and STAT3-mediated apoptosis via IL-10 dependent manner. Journal of Dermatological Science, 2020, 99, 193-202.	1.9	21
78	A case of giant porokeratosis coexisting disseminated superficial porokeratosis. Journal of Cutaneous Immunology and Allergy, 2020, 3, 139-141.	0.3	1
79	First case of symmetrical acral keratoderma in Japan with filaggrin mutation who showed marked improvement in skin manifestations using moisturizer. Journal of Dermatology, 2020, 47, e291-e293.	1.2	1
80	A case of zonisamide-induced toxic epidermal necrolysis with acute respiratory failure. Allergology International, 2020, 69, 642-644.	3.3	3
81	Case of immunoglobulin G4â€related disease presenting with an intramuscular mass. Journal of Dermatology, 2020, 47, e219-e220.	1.2	Ο
82	Wound, pressure ulcer and burn guidelines – 1: Guidelines for wounds in general, second edition. Journal of Dermatology, 2020, 47, 807-833.	1.2	5
83	Genotype and phenotype analysis of patients with pediatric cutaneous mastocytosis, especially wildâ€ŧype KIT patients. Journal of Dermatology, 2020, 47, 426-429.	1.2	9
84	Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Regulates Epidermal Keratinization under Psoriatic Skin Inflammation. American Journal of Pathology, 2020, 190, 577-585.	3.8	26
85	Wound, pressure ulcer and burn guidelines – 4: Guidelines for the management of connective tissue disease/vasculitisâ€associated skin ulcers. Journal of Dermatology, 2020, 47, 1071-1109.	1.2	5
86	Wound, pressure ulcer and burn guidelines – 6: Guidelines for the management of burns, second edition. Journal of Dermatology, 2020, 47, 1207-1235.	1.2	5
87	Vitiligo expansion and extent correlate with durable response in antiâ€programmed death 1 antibody treatment for advanced melanoma: A multiâ€institutional retrospective study. Journal of Dermatology, 2020, 47, 629-635.	1.2	16
88	Association of Dermatomyositis Sine Dermatitis With Anti–Nuclear Matrix Protein 2 Autoantibodies. JAMA Neurology, 2020, 77, 872.	9.0	39
89	Subungual exostosis with postoperative recurrence followed by spontaneous regression. Journal of Dermatology, 2019, 46, e86-e87.	1.2	4
90	Lichen myxedematosus associated with monoclonal gammopathy of undetermined significance: A case report and a review of Japanese patients. Journal of Dermatology, 2019, 46, e32-e33.	1.2	3

#	Article	IF	CITATIONS
91	Autoantibodies detected in patients with vitiligo vulgaris but not in those with rhododendrol-induced leukoderma. Journal of Dermatological Science, 2019, 95, 80-83.	1.9	4
92	Rare case of malignant melanoma presenting expanded volar pigmentation after surgery. Journal of Dermatology, 2019, 46, e409-e410.	1.2	0
93	Distinct Histopathologic Patterns of Finger Eruptions in Dermatomyositis Based on Myositis-Specific Autoantibody Profiles. JAMA Dermatology, 2019, 155, 1080.	4.1	28
94	CD22 and CD72 cooperatively contribute to the development of the reverse Arthus reaction model. Journal of Dermatological Science, 2019, 95, 36-43.	1.9	3
95	Rare case of Leydig cell tumor with type I diabetes mellitus causing female pattern hair loss. Journal of Dermatology, 2019, 46, e484-e486.	1.2	0
96	Case of epidermolytic ichthyosis with impairment of pulmonary function and exacerbated skin manifestations in a late middleâ€aged adult. Journal of Dermatology, 2019, 46, e480-e482.	1.2	0
97	Nail apparatus squamous cell carcinoma mimicking paronychia. Journal of Dermatology, 2019, 46, e460-e461.	1.2	1
98	Case of minocyclineâ€induced hyperpigmentation mimicking angiosarcoma. Journal of Dermatology, 2019, 46, e414-e416.	1.2	2
99	Regulatory B1a Cells Suppress Melanoma Tumor Immunity via IL-10 Production and Inhibiting T Helper Type 1 Cytokine Production in Tumor-Infiltrating CD8+ T Cells. Journal of Investigative Dermatology, 2019, 139, 1535-1544.e1.	0.7	26
100	Immune microenvironment controls the outcome of PDâ€┨ blockade in cutaneous immune response. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 2257-2261.	5.7	5
101	Classification of 3097 patients from the Japanese melanoma study database using the American joint committee on cancer eighth edition cancer staging system. Journal of Dermatological Science, 2019, 94, 284-289.	1.9	13
102	FDG-PET detects extensive calcinosis cutis in anti-NXP2 antibody-positive dermatomyositis. Rheumatology, 2019, 58, 1888-1888.	1.9	3
103	Clinical and histopathological characteristics and survival analysis of 4594 Japanese patients with melanoma. Cancer Medicine, 2019, 8, 2146-2156.	2.8	74
104	Successful treatment of refractory cutaneous lupus vasculitis with i.v. immunoglobulin. Journal of Dermatology, 2019, 46, e253-e255.	1.2	0
105	Correlation between blood cell count and outcome of melanoma patients treated with anti-PD-1 antibodies. Japanese Journal of Clinical Oncology, 2019, 49, 431-437.	1.3	75
106	A toddler case of keratosis follicularis squamosa (Dohi) successfully treated with salicylic acid ointment. European Journal of Dermatology, 2019, 29, 544-546.	0.6	1
107	Anticancer Agent-Induced Life-Threatening Skin Toxicities: A Database Study of Spontaneous Reporting Data. Oncologist, 2019, 24, 266-272.	3.7	3
108	Reconstruction using a vertical "sagging cheek―advancement flap for defects following full-thickness excision of non-melanoma skin cancer in the elderly: a case series. European Journal of Dermatology, 2019, 29, 654-656.	0.6	1

#	Article	IF	CITATIONS
109	Oral pilocarpine alleviates the symptoms of acquired idiopathic generalised anhidrosis. European Journal of Dermatology, 2019, 29, 422-423.	0.6	1
110	Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists. Modern Rheumatology, 2019, 29, 1-19.	1.8	28
111	Pencil ore granuloma with extensive calcinosis: An unusual case report. Journal of Dermatology, 2019, 46, e193-e195.	1.2	1
112	Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists. Journal of Dermatology, 2019, 46, e1-e18.	1.2	13
113	Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists. Neurology and Clinical Neuroscience, 2019, 7, 3-21.	0.4	6
114	Advances in Cutaneous Lupus Erythematosus and Dermatomyositis: A Report from the 4th International Conference on Cutaneous Lupus Erythematosus—An Ongoing Need for International Consensus and Collaborations. Journal of Investigative Dermatology, 2019, 139, 270-276.	0.7	18
115	Linearly distributed multiple lipomas: An unusual case report. Journal of Dermatology, 2019, 46, e175-e176.	1.2	Ο
116	Long-term follow-up of finger passive range of motion in Japanese systemic sclerosis patients treated with self-administered stretching. Modern Rheumatology, 2019, 29, 484-490.	1.8	5
117	Juvenile case of multiple morphea profunda resulting in joint contracture that was successfully treated with cyclosporin A: A case report and review of the published works. Journal of Dermatology, 2019, 46, 354-357.	1.2	10
118	Cutaneous manifestations of dermatomyositis characterized by myositis-specific autoantibodies. F1000Research, 2019, 8, 1951.	1.6	8
119	Possible involvement of IgE antibody in epidermolysis bullosa acquisita: detection and correlation. European Journal of Dermatology, 2019, 29, 210-212.	0.6	1
120	Microcystic adnexal carcinoma with large cysts: unusual clinical presentation and histological findings. European Journal of Dermatology, 2019, 29, 337-339.	0.6	0
121	Tufted angioma of the finger: A case of an uncommon location with unique dermoscopic features. Journal of Dermatology, 2018, 45, e236-e237.	1.2	3
122	Blockade of Granzyme B Remarkably Improves Mucocutaneous Diseases with Keratinocyte Death in Interface Dermatitis. Journal of Investigative Dermatology, 2018, 138, 2079-2083.	0.7	11
123	Diagnostic criteria, severity classification and guidelines of localized scleroderma. Journal of Dermatology, 2018, 45, 755-780.	1.2	51
124	Diagnostic criteria, severity classification and guidelines of systemic sclerosis. Journal of Dermatology, 2018, 45, 633-691.	1.2	35
125	Unusual association between digital mucous cyst and acquired ungual fibrokeratoma: A case report. Journal of Dermatology, 2018, 45, e234-e235.	1.2	0
126	Evidence-based clinical practice guideline for adult Still's disease. Modern Rheumatology, 2018, 28, 736-757.	1.8	42

#	Article	IF	CITATIONS
127	Successful treatment of cutaneous phaeohyphomycosis caused by <i>Exophiala lecaniiâ€corni</i> with voriconazole. Journal of Dermatology, 2018, 45, e271-e272.	1.2	4
128	Reply: Lymph stasis promotes tumor growth. Journal of Dermatological Science, 2018, 90, 367-368.	1.9	0
129	Impact of a new simplified disability scoring system for adult patients with localized scleroderma. Journal of Dermatology, 2018, 45, 431-435.	1.2	2
130	Splicing variant of <i>WDFY4</i> augments MDA5 signalling and the risk of clinically amyopathic dermatomyositis. Annals of the Rheumatic Diseases, 2018, 77, 602-611.	0.9	51
131	Diagnostic criteria, severity classification and guidelines of lichen sclerosus et atrophicus. Journal of Dermatology, 2018, 45, 891-897.	1.2	17
132	Surgical damage to the lymphatic system promotes tumor growth via impaired adaptive immune response. Journal of Dermatological Science, 2018, 90, 46-51.	1.9	9
133	Blastic plasmacytoid dendritic cell neoplasm arising from clonal hematopoiesis. International Journal of Hematology, 2018, 108, 447-451.	1.6	7
134	Case with anaphylactic shock induced by heparinâ€lock flush injection. Journal of Dermatology, 2018, 45, e195-e196.	1.2	2
135	Congenital peristernal dermal sinus: A case report and published work review. Journal of Dermatology, 2018, 45, e242-e243.	1.2	5
136	Diagnostic criteria, severity classification and guidelines of eosinophilic fasciitis. Journal of Dermatology, 2018, 45, 881-890.	1.2	50
137	Neurofibromatosis type 1-associated serious haemorrhagic events successfully treated with steroid pulse therapy. European Journal of Dermatology, 2018, 28, 382-384.	0.6	2
138	A case of cutaneous angiosarcoma successfully treated with eribulin. European Journal of Dermatology, 2018, 28, 410-412.	0.6	5
139	Bullous pemphigoid accompanied by IgA nephropathy and atypical haemolytic uraemic syndrome. European Journal of Dermatology, 2018, 28, 421-422.	0.6	4
140	Bilateral metachronous cutaneous apocrine carcinoma with reduced PTEN expression. European Journal of Dermatology, 2018, 28, 372-374.	0.6	0
141	Trichostasis spinulosa arising in isolated collagenoma of the scalp. European Journal of Dermatology, 2018, 28, 531-532.	0.6	2
142	Multiple haemangiomas in TAFRO syndrome with atypical features of glomeruloid and epithelioid haemangiomas. European Journal of Dermatology, 2018, 28, 371-372.	0.6	2
143	Subungual melanoma complicated by hydroxyurea-induced melanonychia with non-melanoma Hutchinson's sign. European Journal of Dermatology, 2018, 28, 559-561.	0.6	3
144	Depigmented extramammary Paget's disease without histological dermal invasion identified by multiple inguinal and pelvic lymph node metastases. European Journal of Dermatology, 2018, 28, 387-388.	0.6	4

#	Article	IF	CITATIONS
145	Nation-wide survey of advanced non-melanoma skin cancers treated at dermatology departments in Japan. Journal of Dermatological Science, 2018, 92, 230-236.	1.9	11
146	Coccygeal Nodule in an Infant: A Quiz. Acta Dermato-Venereologica, 2018, 98, 824-825.	1.3	1
147	Use of immune checkpoint inhibitors prolonged overall survival in a Japanese population of advanced malignant melanoma patients: Retrospective single institutional study. Journal of Dermatology, 2018, 45, 1337-1339.	1.2	16
148	A Case of Refractory Subcutaneous Panniculitis-like T-cell Lymphoma with Bone Marrow and Lung Involvement Treated Successfully with Oral Etoposide. Acta Dermato-Venereologica, 2018, 98, 610-611.	1.3	2
149	Cutaneous Angiosarcoma: The Possibility of New Treatment Options Especially for Patients with Large Primary Tumor. Frontiers in Oncology, 2018, 8, 46.	2.8	68
150	BAFF inhibition attenuates fibrosis in scleroderma by modulating the regulatory and effector B cell balance. Science Advances, 2018, 4, eaas9944.	10.3	98
151	Negativeâ€pressure closure was superior to tieâ€over technique for stabilization of splitâ€thickness skin graft in large or muscleâ€exposing defects: A retrospective study. Journal of Dermatology, 2018, 45, 1207-1210.	1.2	13
152	Trabectedin treatment for imatinib/pazopanib-resistant dermatofibrosarcoma protuberans : A case report. Skin Cancer, 2018, 33, 30-34.	0.0	0
153	Third-line pembrolizumab-induced immune-related interstitial pneumonitis after ipilimumab and nivolumab failure. European Journal of Dermatology, 2018, 28, 129-130.	0.6	4
154	Pegylated interferon- $\hat{1}\pm 2b$ for local control of Langerhans cell sarcoma. European Journal of Dermatology, 2018, 28, 835-836.	0.6	2
155	Pelvic reactive lymphadenopathy mimicking lymph node metastasis of heel malignant melanoma. European Journal of Dermatology, 2018, 28, 841-843.	0.6	Ο
156	Serum level of interleukin-6 is increased in nivolumab-associated psoriasiform dermatitis and tumor necrosis factor-α is a biomarker of nivolumab recativity. Journal of Dermatological Science, 2017, 86, 71-73.	1.9	105
157	Three cases of interstitial pneumonia with anti-signal recognition particle antibody. Allergology International, 2017, 66, 485-487.	3.3	5
158	Taxaneâ€induced sclerodermaâ€like skin changes resulting in gangrene: A case report. Journal of Dermatology, 2017, 44, e54-e55.	1.2	6
159	Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041). Cancer Chemotherapy and Pharmacology, 2017, 79, 651-660.	2.3	76
160	Cutaneous surgery under local anesthesia in very elderly patients 90Âyears of age and older is as safe as in elderly patients ranging in age from 75 to 80Âyears old. International Journal of Dermatology, 2017, 56, 681-685.	1.0	9
161	Case of facial lupus erythematosus profundus with intractable ulceration successfully treated with dapsone. Journal of Dermatology, 2017, 44, e89-e90.	1.2	1
162	Pyoderma gangrenosum and underlying diseases in Japanese patients: A regional longâ€ŧerm study. Journal of Dermatology, 2017, 44, 1281-1284.	1.2	13

#	Article	IF	CITATIONS
163	Eosinophilic granulomatosis with polyangiitis followed by venous thromboembolism resulting in severe cutaneous ulcers. Journal of Dermatology, 2017, 44, e216-e217.	1.2	Ο
164	RXRB Is an MHC-Encoded Susceptibility Gene Associated with Anti-Topoisomerase IÂAntibody-Positive Systemic Sclerosis. Journal of Investigative Dermatology, 2017, 137, 1878-1886.	0.7	3
165	The rate of facial nerve dysfunction and time to recovery after intraparotid and extraparotid facial nerve exposure and protection in head and neck cutaneous tumor surgery. International Journal of Clinical Oncology, 2017, 22, 843-848.	2.2	8
166	Polymyalgia rheumatica in a melanoma patient due to nivolumab treatment. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1357-1358.	2.5	15
167	Blockade of p38 Mitogen-Activated Protein Kinase Inhibits Murine Sclerodermatous Chronic Graft-versus-Host Disease. American Journal of Pathology, 2017, 187, 841-850.	3.8	18
168	Transethnic meta-analysis identifies <i>GSDMA</i> and <i>PRDM1</i> as susceptibility genes to systemic sclerosis. Annals of the Rheumatic Diseases, 2017, 76, 1150-1158.	0.9	77
169	Efficacy and safety of nivolumab in Japanese patients with previously untreated advanced melanoma: A phase <scp>II</scp> study. Cancer Science, 2017, 108, 1223-1230.	3.9	66
170	Behandlung eines kutanen Plattenepithelkarzinoms mit intraarterieller Radiochemotherapie. JDDG - Journal of the German Society of Dermatology, 2017, 15, 724-726.	0.8	0
171	Polymyositis induced by PD-1 blockade in a patient in hepatitis B remission. Journal of the Neurological Sciences, 2017, 381, 22-24.	0.6	4
172	Clear cell sarcoma of the scalp: A case report. Journal of Dermatology, 2017, 44, e276-e277.	1.2	1
173	Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: A multiâ€institutional retrospective study. Journal of Dermatology, 2017, 44, 117-122.	1.2	170
174	Clinical and histological characteristics of livedo racemosa in essential thrombocythemia: A report of two cases and review of the published works. Journal of Dermatology, 2017, 44, 84-87.	1.2	7
175	Availability of sentinel lymph node biopsy for cutaneous squamous cell carcinoma. Journal of Dermatology, 2017, 44, 431-437.	1.2	10
176	Autoantibody to scaffold attachment factor B (SAFB): A novel connective tissue disease-related autoantibody associated with interstitial lung disease. Journal of Autoimmunity, 2017, 76, 101-107.	6.5	4
177	Azathioprine combination therapy for steroid-refractory hepatic immune system-related adverse events. European Journal of Dermatology, 2017, 27, 301-303.	0.6	21
178	Severe hepatitis arising from ipilimumab administration, following melanoma treatment with nivolumab. Japanese Journal of Clinical Oncology, 2017, 47, 175-178.	1.3	52
179	Cutaneous squamous cell carcinoma treated with preoperative intraarterial chemoradiation therapy. JDDG - Journal of the German Society of Dermatology, 2017, 15, 724-726.	0.8	2
180	Clinical Utility of an Enzyme-Linked Immunosorbent Assay for Detecting Anti-Melanoma Differentiation-Associated Gene 5 Autoantibodies. PLoS ONE, 2016, 11, e0154285.	2.5	102

#	Article	IF	CITATIONS
181	Angioimmunoblastic Tâ€cell lymphoma mimicking dermatomyositis. Journal of Dermatology, 2016, 43, 837-839.	1.2	5
182	A proposal for a TNM staging system for extramammary Paget disease: Retrospective analysis of 301 patients with invasive primary tumors. Journal of Dermatological Science, 2016, 83, 234-239.	1.9	112
183	Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillain–Barré syndrome: a case report. Japanese Journal of Clinical Oncology, 2016, 46, 875-878.	1.3	70
184	The wound/burn guidelines – 6: Guidelines for the management of burns. Journal of Dermatology, 2016, 43, 989-1010.	1.2	48
185	Scleroderma-like skin changes occurring after the use of paclitaxel without any chemical solvents: a first case report. European Journal of Dermatology, 2016, 26, 317-318.	0.6	7
186	Marginal zone B cells exacerbate endotoxic shock via interleukin-6 secretion induced by Fcα/μR-coupled TLR4 signalling. Nature Communications, 2016, 7, 11498.	12.8	49
187	Recent advances in dermatomyositis-specific autoantibodies. Current Opinion in Rheumatology, 2016, 28, 636-644.	4.3	125
188	Nivolumab-induced thyroid dysfunction. Japanese Journal of Clinical Oncology, 2016, 46, 575-579.	1.3	44
189	Enzyme-linked immunosorbent assays for detection of anti-transcriptional intermediary factor-1 gamma and anti-Mi-2 autoantibodies in dermatomyositis. Journal of Dermatological Science, 2016, 84, 272-281.	1.9	69
190	Risk Factors for Developing Skeletal-Related Events in Breast Cancer Patients With Bone Metastases Undergoing Treatment With Bone-Modifying Agents. Oncologist, 2016, 21, 508-513.	3.7	31
191	The wound/burn guidelines – 2: Guidelines for the diagnosis and treatment for pressure ulcers. Journal of Dermatology, 2016, 43, 469-506.	1.2	11
192	The wound/burn guidelines – 1: Wounds in general. Journal of Dermatology, 2016, 43, 357-375.	1.2	7
193	The wound/burn guidelines – 3: Guidelines for the diagnosis and treatment for diabetic ulcer/gangrene. Journal of Dermatology, 2016, 43, 591-619.	1.2	14
194	Immunoglobulin A vasculitis associated with HIV infection. Journal of Dermatology, 2016, 43, 444-445.	1.2	4
195	Concordance of the HER2 protein and gene status between primary and corresponding lymph node metastatic sites of extramammary Paget disease. Clinical and Experimental Metastasis, 2016, 33, 687-697.	3.3	15
196	The wound/burn guidelines – 4: Guidelines for the management of skin ulcers associated with connective tissue disease/vasculitis. Journal of Dermatology, 2016, 43, 729-757.	1.2	17
197	The wound/burn guidelines – 5: Guidelines for the management of lower leg ulcers/varicose veins. Journal of Dermatology, 2016, 43, 853-868.	1.2	6
198	A novel splenic B1 regulatory cell subset suppresses allergic disease through phosphatidylinositol 3-kinase–Akt pathway activation. Journal of Allergy and Clinical Immunology, 2016, 138, 1170-1182.e9.	2.9	54

#	Article	IF	CITATIONS
199	Anti-MDA-5 antibody-positive bullous dermatomyositis with palmar papules complicating rapidly progressive interstitial lung disease. Modern Rheumatology, 2016, 26, 614-616.	1.8	8
200	Decreased levels of regulatory B cells in patients with systemic sclerosis: association with autoantibody production and disease activity. Rheumatology, 2016, 55, 263-267.	1.9	84
201	Human Leukocyte Antigen and Systemic Sclerosis in Japanese: The Sign of the Four Independent Protective Alleles, DRB1*13:02, DRB1*14:06, DQB1*03:01, and DPB1*02:01. PLoS ONE, 2016, 11, e0154255.	2.5	25
202	Oropharyngeal Dysphagia in Dermatomyositis: Associations with Clinical and Laboratory Features Including Autoantibodies. PLoS ONE, 2016, 11, e0154746.	2.5	78
203	Nodulocystic basal cell carcinoma arising directly from a seborrheic keratosis: A rare case report. Indian Journal of Dermatology, 2016, 61, 443.	0.3	6
204	Transforming Growth Factor-ß and Connective Tissue Growth Factor. , 2016, , 137-153.		0
205	B Cells. , 2016, , 113-130.		0
206	Reply. Arthritis and Rheumatology, 2015, 67, 2548-2548.	5.6	1
207	Angiosarcoma of the scalp in a patient with systemic sclerosis. Journal of Dermatology, 2015, 42, 102-104.	1.2	5
208	A novel approach for inguinal lymph node dissection without inguinal skin incision for invasive extramammary Paget disease. Dermatologic Therapy, 2015, 28, 351-354.	1.7	3
209	Effects of nonâ€amputative wide local excision on the local control and prognosis of <i>inÂsitu</i> and invasive subungual melanoma. Journal of Dermatology, 2015, 42, 861-866.	1.2	37
210	Childhoodâ€Onset Antiâ€Ku Antibodyâ€Positive Generalized Morphea with Polymyositis: A Japanese Case Study. Pediatric Dermatology, 2015, 32, e224-5.	0.9	4
211	The role of sentinel lymph node biopsy in the management of invasive extramammary Paget's disease: Multi-center, retrospective study of 151 patients. Journal of Dermatological Science, 2015, 79, 38-42.	1.9	67
212	Proteomic identification of heterogeneous nuclear ribonucleoprotein K as a novel cold-associated autoantigen in patients with secondary Raynaud's phenomenon. Rheumatology, 2015, 54, 349-358.	1.9	14
213	Serum interferon-α is a useful biomarker in patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis. Modern Rheumatology, 2015, 25, 85-89.	1.8	66
214	Clinical perspectives and murine models of lichenoid tissue reaction/interface dermatitis. Journal of Dermatological Science, 2015, 78, 167-172.	1.9	22
215	Regulatory B cells in human inflammatory and autoimmune diseases: from mouse models to clinical research. International Immunology, 2015, 27, 495-504.	4.0	88
216	Clinical and Immunologic Predictors of Scleroderma Renal Crisis in Japanese Systemic Sclerosis Patients With Anti–RNA Polymerase III Autoantibodies. Arthritis and Rheumatology, 2015, 67, 1045-1052.	5.6	70

#	Article	IF	CITATIONS
217	High incidence of pulmonary arterial hypertension in systemic sclerosis patients with anti-centriole autoantibodies. Modern Rheumatology, 2015, 25, 798-801.	1.8	11
218	Experimental myositis inducible with transfer of dendritic cells presenting a skeletal muscle C protein-derived CD8 epitope peptide. International Immunology, 2015, 27, 327-332.	4.0	10
219	Statistics for malignant melanoma in Japan : A nation wide survey from 2005 to 2013. Skin Cancer, 2015, 29, 189-194.	0.0	9
220	Anti-MDA5 antibody-positive dermatomyositis with lethal progressive interstitial lung disease and advanced gastric cancer. European Journal of Dermatology, 2014, 24, 490-491.	0.6	11
221	The clinical characteristics of juvenile-onset systemic sclerosis in Japanese patients. Modern Rheumatology, 2014, 24, 377-379.	1.8	5
222	Pemphigus Foliaceus Associated with Anti-NXP2 Autoantibody-positive Dermatomyositis. Acta Dermato-Venereologica, 2014, 94, 478-479.	1.3	7
223	A Crucial Role of Lâ€Selectin in C Protein–Induced Experimental Polymyositis in Mice. Arthritis and Rheumatology, 2014, 66, 1864-1871.	5.6	16
224	Detection of anti-CADM-140/MDA5 antibodies in a patient with classic dermatomyositis developing rapidly progressive interstitial lung disease. Journal of Dermatology, 2014, 41, 664-665.	1.2	6
225	Axillary giant lipoma: A report of two cases and published work review. Journal of Dermatology, 2014, 41, 841-844.	1.2	9
226	Autoantibodies to RuvBL1 and RuvBL2: A Novel Systemic Sclerosis–Related Antibody Associated With Diffuse Cutaneous and Skeletal Muscle Involvement. Arthritis Care and Research, 2014, 66, 575-584.	3.4	86
227	Metastatic cutaneous apocrine carcinoma of the axilla successfully treated using systemic chemotherapy with i.v. epirubicin and cyclophosphamide followed by oral fluorinated pyrimidine. Journal of Dermatology, 2014, 41, 280-282.	1.2	9
228	Tumorâ€toâ€bone distance of invasive subungual melanoma: An analysis of 30 cases. Journal of Dermatology, 2014, 41, 872-877.	1.2	26
229	Case of pigmented epithelioid melanocytoma with lymph node metastases. Journal of Dermatology, 2014, 41, 452-453.	1.2	4
230	Blockade of Syk ameliorates the development of murine sclerodermatous chronic graft-versus-host disease. Journal of Dermatological Science, 2014, 74, 214-221.	1.9	37
231	Surgical management of umbilical basal cell carcinoma: Published work review and the optimal depth of surgical excision. Journal of Dermatology, 2014, 41, 992-995.	1.2	8
232	B Cells Promote Tumor Immunity against B16F10 Melanoma. American Journal of Pathology, 2014, 184, 3120-3129.	3.8	28
233	A Case of Dermatomyositis with Esophageal Fistula in Whom Blind Mucosal Biopsy Detected Occult Oropharyngeal Carcinoma. Case Reports in Dermatology, 2014, 6, 268-273.	0.8	2
234	Serum Adhesion Molecule Levels as Prognostic Markers in Patients with Early Systemic Sclerosis: A Multicentre, Prospective, Observational Study. PLoS ONE, 2014, 9, e88150.	2.5	38

Манави Гилиото

#	Article	IF	CITATIONS
235	Serum chemokine levels as prognostic markers in patients with early systemic sclerosis: a multicenter, prospective, observational study. Modern Rheumatology, 2013, 23, 1076-84.	1.8	13
236	Clinical, serologic and magnetic resonance imaging of 3 cases of inflammatory myopathy with abundant macrophages in the Japanese population. Rheumatology International, 2013, 33, 1059-1064.	3.0	5
237	Chemokine receptors CCR2 and CX3CR1 regulate skin fibrosis in the mouse model of cytokine-induced systemic sclerosis. Journal of Dermatological Science, 2013, 69, 250-258.	1.9	45
238	Augmented ICOS expression in patients with early diffuse cutaneous systemic sclerosis. Rheumatology, 2013, 52, 242-251.	1.9	21
239	The clinical characteristics of juvenile-onset systemic sclerosis in Japanese patients. Modern Rheumatology, 2013, , 1.	1.8	3
240	Early diagnosis and treatment for remission of clinically amyopathic dermatomyositis complicated by rapid progress interstitial lung disease: a report of two cases. Modern Rheumatology, 2013, 23, 190-194.	1.8	21
241	Dermokine inhibits ELR+CXC chemokine expression and delays early skin wound healing. Journal of Dermatological Science, 2013, 70, 34-41.	1.9	28
242	B-cell linker protein expression contributes to controlling allergic and autoimmune diseases by mediating IL-10 production in regulatory B cells. Journal of Allergy and Clinical Immunology, 2013, 131, 1674-1682.e9.	2.9	76
243	Donor-derived regulatory B cells are important for suppression of murine sclerodermatous chronic graft-versus-host disease. Blood, 2013, 121, 3274-3283.	1.4	92
244	Circulating γ/δT cells in systemic sclerosis exhibit activated phenotype and enhance gene expression of proalpha2(I) collagen of fibroblasts. Journal of Dermatological Science, 2013, 69, 54-60.	1.9	16
245	miR-150 Down-Regulation Contributes to the Constitutive Type I Collagen Overexpression in Scleroderma Dermal Fibroblasts via the Induction ofÂIntegrin 123. American Journal of Pathology, 2013, 182, 206-216.	3.8	124
246	Scleroderma: recent lessons from murine models and implications for future therapeutics. Expert Review of Dermatology, 2013, 8, 527-539.	0.3	4
247	Clinical and laboratory features dependent on age at onset in Japanese systemic sclerosis. Modern Rheumatology, 2013, 23, 913-919.	1.8	3
248	FTY720 Ameliorates Murine Sclerodermatous Chronic Graftâ€Versusâ€Host Disease by Promoting Expansion of Splenic Regulatory Cells and Inhibiting Immune Cell Infiltration Into Skin. Arthritis and Rheumatism, 2013, 65, 1624-1635.	6.7	40
249	TIF1γ-overexpressing, Highly Progressive Endometrial Carcinoma in a Patient with Dermato-myositis Positive for Malignancy-associated Anti-p155/140 Autoantibody. Acta Dermato-Venereologica, 2013, 93, 715-716.	1.3	30
250	Anti-topoisomerase I antibody levels as serum markers of skin sclerosis in systemic sclerosis. Journal of Dermatology, 2013, 40, 89-93.	1.2	9
251	Serum chemokine levels as prognostic markers in patients with early systemic sclerosis: a multicenter, prospective, observational study. Modern Rheumatology, 2013, 23, 1076-1084.	1.8	28
252	Case report of anti-transcription intermediary factor-1-γ/α antibody-positive dermatomyositis associated with gastric cancer and immunoglobulin G4-positive pulmonary inflammatory pseudotumor. Journal of Dermatology, 2013, 40, 567-569.	1.2	14

#	Article	IF	CITATIONS
253	Autoantibodies to small ubiquitin-like modifier activating enzymes in Japanese patients with dermatomyositis: comparison with a UK Caucasian cohort. Annals of the Rheumatic Diseases, 2013, 72, 151-153.	0.9	77
254	Cutaneous Mycobacterium chelonae infection in a rheumatoid arthritis patient treated with etanercept. European Journal of Dermatology, 2013, 23, 700-701.	0.6	0
255	Common and Distinct Clinical Features in Adult Patients with Anti-Aminoacyl-tRNA Synthetase Antibodies: Heterogeneity within the Syndrome. PLoS ONE, 2013, 8, e60442.	2.5	306
256	Early diagnosis and treatment for remission of clinically amyopathic dermatomyositis complicated by rapid progress interstitial lung disease: a report of two cases. Modern Rheumatology, 2013, 23, 190-194.	1.8	6
257	Clinical and laboratory features dependent on age at onset in Japanese systemic sclerosis. Modern Rheumatology, 2013, 23, 913-919.	1.8	7
258	Prurigo nodularis-like skin eruptions in a patient with IgG4-related disease. European Journal of Dermatology, 2013, 23, 541-542.	0.6	4
259	Cutaneous necrotizing vasculitis in a patient with dermatomyositis positive for anti-PL-7 antibody. European Journal of Dermatology, 2013, 23, 889-890.	0.6	3
260	Impaired IL-17 Signaling Pathway Contributes to the Increased Collagen Expression in Scleroderma Fibroblasts. Journal of Immunology, 2012, 188, 3573-3583.	0.8	188
261	Investigation of prognostic factors for skin sclerosis and lung function in Japanese patients with early systemic sclerosis: a multicentre prospective observational study. Rheumatology, 2012, 51, 129-133.	1.9	12
262	IL-6 Blockade Attenuates the Development of Murine Sclerodermatous Chronic Graft-Versus-Host Disease. Journal of Investigative Dermatology, 2012, 132, 2752-2761.	0.7	55
263	TGF-β–Mediated Downregulation of MicroRNA-196a Contributes to the Constitutive Upregulated Type I Collagen Expression in Scleroderma Dermal Fibroblasts. Journal of Immunology, 2012, 188, 3323-3331.	0.8	138
264	Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Annals of the Rheumatic Diseases, 2012, 71, 710-713.	0.9	220
265	Association ofUBE2L3polymorphisms with diffuse cutaneous systemic sclerosis in a Japanese population: Table 1. Annals of the Rheumatic Diseases, 2012, 71, 1259-1260.	0.9	7
266	High prevalence of primary biliary cirrhosis and disease-associated autoantibodies in Japanese patients with systemic sclerosis. Modern Rheumatology, 2012, 22, 892-898.	1.8	29
267	The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatology, 2012, 51, 1278-1284.	1.9	252
268	Two young-adult female cases of dermatomyositis with antibodies for transcriptional intermediary factor 1-Î ³ . European Journal of Dermatology, 2012, 22, 668-671.	0.6	4
269	Two cases of livedo vasculopathy with nonâ€criteria antiphospholipid antibodies. Journal of Dermatology, 2012, 39, 1026-1030.	1.2	2
270	Potential roles of interleukinâ€17A in the development of skin fibrosis in mice. Arthritis and Rheumatism, 2012, 64, 3726-3735.	6.7	118

#	Article	IF	CITATIONS
271	Host-Derived MCP-1 and MIP-1α Regulate Protective Anti-Tumor Immunity to Localized and Metastatic B16 Melanoma. American Journal of Pathology, 2012, 180, 365-374.	3.8	47
272	Increased Accumulation of Extracellular Thrombospondin-2 Due to Low Degradation Activity Stimulates Type I Collagen Expression in Scleroderma Fibroblasts. American Journal of Pathology, 2012, 180, 703-714.	3.8	53
273	Basophils and mast cells play critical roles for leukocyte recruitment in IgE-mediated cutaneous reverse passive Arthus reaction. Journal of Dermatological Science, 2012, 67, 181-189.	1.9	10
274	Dermatomyositis: Myositisâ€ s pecific autoantibodies and skin manifestations. Clinical and Experimental Neuroimmunology, 2012, 3, 74-84.	1.0	6
275	Adultâ€onset Still's disease with dermatomyositisâ€like eruption. Journal of Dermatology, 2012, 39, 958-960.	1.2	9
276	Skin sclerosis as a manifestation of POEMS syndrome. Journal of Dermatology, 2012, 39, 922-926.	1.2	7
277	CD22 serves as a receptor for soluble IgM. European Journal of Immunology, 2012, 42, 241-247.	2.9	38
278	Myositisâ€specific antiâ€155/140 autoantibodies target transcription intermediary factor 1 family proteins. Arthritis and Rheumatism, 2012, 64, 513-522.	6.7	245
279	High prevalence of primary biliary cirrhosis and disease-associated autoantibodies in Japanese patients with systemic sclerosis. Modern Rheumatology, 2012, 22, 892-898.	1.8	16
280	A Case of Anti-EJ Antibody-Positive Dermatomyositis with Severe Palpebral Edema. Nishinihon Journal of Dermatology, 2012, 74, 488-492.	0.0	0
281	The roles of P- and E-selectins and P-selectin glycoprotein ligand-1 in primary and metastatic mouse melanomas. Journal of Dermatological Science, 2011, 64, 99-107.	1.9	9
282	Inducible Costimulator (ICOS) and ICOS Ligand Signaling Has Pivotal Roles in Skin Wound Healing via Cytokine Production. American Journal of Pathology, 2011, 179, 2360-2369.	3.8	36
283	Serum chemokine and cytokine levels as indicators of disease activity in patients with systemic sclerosis. Clinical Rheumatology, 2011, 30, 231-237.	2.2	78
284	Dermatomyositis with anti-OJ antibody. Rheumatology International, 2011, 31, 1673-1675.	3.0	6
285	IgG4-Related Skin Disease, a Mimic of Angiolymphoid Hyperplasia with Eosinophilia. Dermatology, 2011, 223, 301-305.	2.1	39
286	Use of Serum Clara Cell 16-kDa (CC16) Levels as a Potential Indicator of Active Pulmonary Fibrosis in Systemic Sclerosis. Journal of Rheumatology, 2011, 38, 877-884.	2.0	47
287	Association between nail-fold capillary findings and disease activity in dermatomyositis. Rheumatology, 2011, 50, 1091-1098.	1.9	63
288	Clinical Correlations With Dermatomyositis-Specific Autoantibodies in Adult Japanese Patients With Dermatology, 2011, 147, 391.	1.4	293

#	Article	IF	CITATIONS
289	Elevated serum interleukin-27 levels in patients with systemic sclerosis: association with T cell, B cell and fibroblast activation. Annals of the Rheumatic Diseases, 2011, 70, 194-200.	0.9	54
290	Anti-p155/140 Antibody-positive Dermatomyositis with Metastasis OriginaÂŧing from an Unknown Site. Acta Dermato-Venereologica, 2011, 91, 84-85.	1.3	7
291	Clinical and Pathological Findings of Interstitial Lung Disease Patients with Anti-Aminoacyl-tRNA Synthetase Autoantibodies. Internal Medicine, 2010, 49, 361-369.	0.7	121
292	Autoantibody against caspase-3, an executioner of apoptosis, in patients with systemic sclerosis. Rheumatology International, 2010, 30, 871-878.	3.0	10
293	Autoantibody against one of the antioxidant repair enzymes, methionine sulfoxide reductase A, in systemic sclerosis: association with pulmonary fibrosis and vascular damage. Archives of Dermatological Research, 2010, 302, 27-35.	1.9	33
294	Differential phosphorylation of functional tyrosines in CD19 modulates Bâ€lymphocyte activation. European Journal of Immunology, 2010, 40, 1192-1204.	2.9	18
295	Association of the <i>FAM167A–BLK</i> region with systemic sclerosis. Arthritis and Rheumatism, 2010, 62, 890-895.	6.7	76
296	Inducible costimulator ligand regulates bleomycinâ€induced lung and skin fibrosis in a mouse model independently of the inducible costimulator/inducible costimulator ligand pathway. Arthritis and Rheumatism, 2010, 62, 1723-1732.	6.7	45
297	Treatment with rapamycin prevents fibrosis in tightâ€skin and bleomycinâ€induced mouse models of systemic sclerosis. Arthritis and Rheumatism, 2010, 62, 2476-2487.	6.7	118
298	Herpetiform pemphigus without antiâ€desmoglein 1/3 autoantibodies. Journal of Dermatology, 2010, 37, 264-268.	1.2	8
299	Intractable genital ulcers from herpes simplex virus reactivation in drugâ€induced hypersensitivity syndrome caused by allopurinol. International Journal of Dermatology, 2010, 49, 700-704.	1.0	16
300	Elevated Serum Concentrations of Triggering Receptor Expressed on Myeloid Cells-1 in Diffuse Cutaneous Systemic Sclerosis: Association with Severity of Pulmonary Fibrosis. Journal of Rheumatology, 2010, 37, 787-791.	2.0	6
301	Regulatory B Cells (B10 Cells) Have a Suppressive Role in Murine Lupus: CD19 and B10 Cell Deficiency Exacerbates Systemic Autoimmunity. Journal of Immunology, 2010, 184, 4801-4809.	0.8	274
302	CD22 Expression Mediates the Regulatory Functions of Peritoneal B-1a Cells during the Remission Phase of Contact Hypersensitivity Reactions. Journal of Immunology, 2010, 184, 4637-4645.	0.8	52
303	Protective and Pathogenic Roles for B Cells during Systemic Autoimmunity in NZB/W F1 Mice. Journal of Immunology, 2010, 184, 4789-4800.	0.8	136
304	Usefulness of anti-cyclic citrullinated peptide antibody and rheumatoid factor to detect rheumatoid arthritis in patients with systemic sclerosis. Rheumatology, 2010, 49, 2135-2139.	1.9	32
305	Cell Adhesion Molecules Regulate Fibrotic Process via Th1/Th2/Th17 Cell Balance in a Bleomycin-Induced Scleroderma Model. Journal of Immunology, 2010, 185, 2502-2515.	0.8	126
306	The Differential Role of L-Selectin and ICAM-1 in Th1-Type and Th2-Type Contact Hypersensitivity. Journal of Investigative Dermatology, 2010, 130, 1558-1570.	0.7	24

#	Article	IF	CITATIONS
307	Elevated serum placenta growth factor (PIGF) levels in patients with systemic sclerosis: A possible role in the development of skin but not lung fibrosis. Journal of Dermatological Science, 2010, 58, 229-231.	1.9	6
308	Regulatory B cells in skin and connective tissue diseases. Journal of Dermatological Science, 2010, 60, 1-7.	1.9	29
309	Re-emergence of anti-topoisomerase I antibody with exacerbated development of skin sclerosis in a patient with systemic sclerosis. Journal of the American Academy of Dermatology, 2010, 62, 142-144.	1.2	5
310	Platelets Control Leukocyte Recruitment in a Murine Model of Cutaneous Arthus Reaction. American Journal of Pathology, 2010, 176, 259-269.	3.8	57
311	Skin Manifestations in Rheumatologic Disorders. , 2010, , 349-356.		0
312	Increased Serum Pentraxin 3 in Patients with Systemic Sclerosis. Journal of Rheumatology, 2009, 36, 976-983.	2.0	41
313	Expression of cytokines and chemokines in bullous pemphigoid. Expert Review of Dermatology, 2009, 4, 321-327.	0.3	5
314	Serum CXCL16 Concentrations Correlate with the Extent of Skin Sclerosis in Patients with Systemic Sclerosis. Journal of Rheumatology, 2009, 36, 1917-1923.	2.0	17
315	Reduced red blood cell velocity in nail-fold capillaries as a sensitive and specific indicator of microcirculation injury in systemic sclerosis. Rheumatology, 2009, 48, 696-703.	1.9	47
316	Association of a functional polymorphism in the <i>IRF5</i> region with systemic sclerosis in a Japanese population. Arthritis and Rheumatism, 2009, 60, 1845-1850.	6.7	115
317	A novel inhibitor of Smadâ€dependent transcriptional activation suppresses tissue fibrosis in mouse models of systemic sclerosis. Arthritis and Rheumatism, 2009, 60, 3465-3475.	6.7	49
318	Clinical Significance of Serum HMGB-1 and sRAGE Levels in Systemic Sclerosis: Association with Disease Severity. Journal of Clinical Immunology, 2009, 29, 180-189.	3.8	96
319	Esophageal transit scintigraphy and structured questionnaire in patients with systemic sclerosis with endoscopically proven reflux esophagitis. Annals of Nuclear Medicine, 2009, 23, 771-776.	2.2	6
320	P-Selectin Glycoprotein Ligand-1 Contributes to Wound Healing Predominantly as a P-Selectin Ligand and Partly as an E-Selectin Ligand. Journal of Investigative Dermatology, 2009, 129, 2059-2067.	0.7	11
321	Low Zone Tolerance Requires ICAM-1 Expression to Limit Contact Hypersensitivity Elicitation. Journal of Investigative Dermatology, 2009, 129, 2661-2667.	0.7	2
322	Elevated Circulating TWEAK Levels in Systemic Sclerosis: Association with Lower Frequency of Pulmonary Fibrosis. Journal of Rheumatology, 2009, 36, 1657-1662.	2.0	25
323	A Conserved Salt Bridge in the G Loop of Multiple Protein Kinases Is Important for Catalysis and for In Vivo Lyn Function. Molecular Cell, 2009, 33, 43-52.	9.7	34
324	Clinical association of serum CD137 (4-1BB) levels in patients with systemic sclerosis. Journal of Dermatological Science, 2009, 53, 159-161.	1.9	3

#	Article	IF	CITATIONS
325	Bosentan increases serum IL-12 levels in systemic sclerosis patients with pulmonary arterial hypertension. Journal of Dermatological Science, 2009, 55, 66-67.	1.9	8
326	Decreased levels of autoantibody against histone deacetylase 3 in patients with systemic sclerosis. Autoimmunity, 2009, 42, 120-125.	2.6	14
327	Establishment of Experimental Eosinophilic Vasculitis by IgE-Mediated Cutaneous Reverse Passive Arthus Reaction. American Journal of Pathology, 2009, 174, 2225-2233.	3.8	15
328	CD19, a Response Regulator of B Lymphocytes, Regulates Wound Healing through Hyaluronan-Induced TLR4 Signaling. American Journal of Pathology, 2009, 175, 649-660.	3.8	84
329	Elevated Serum Concentrations of Polymorphonuclear Neutrophilic Leukocyte Elastase in Systemic Sclerosis: Association with Pulmonary Fibrosis. Journal of Rheumatology, 2009, 36, 99-105.	2.0	15
330	A Case of Systemic Sclerosis Occurring after Paclitaxel Therapy. Nishinihon Journal of Dermatology, 2009, 71, 556-560.	0.0	1
331	Neutralizing monoclonal antibody to human connective tissue growth factor ameliorates transforming growth factorâ€Î²â€induced mouse fibrosis. Journal of Cellular Physiology, 2008, 216, 680-687.	4.1	66
332	CD19 regulates the development of bleomycinâ€induced pulmonary fibrosis in a mouse model. Arthritis and Rheumatism, 2008, 58, 3574-3584.	6.7	73
333	Elevated serum levels of APRIL, but not BAFF, in patients with atopic dermatitis. Experimental Dermatology, 2008, 17, 197-202.	2.9	21
334	The Loss of MCP-1 Attenuates Cutaneous Ischemia–Reperfusion Injury in a Mouse Model of Pressure Ulcer. Journal of Investigative Dermatology, 2008, 128, 1838-1851.	0.7	64
335	Serum levels of IgE anti-BP180 and anti-BP230 autoantibodies in patients with bullous pemphigoid. Journal of Dermatological Science, 2008, 49, 153-161.	1.9	85
336	Clinical association of serum interleukin-17 levels in systemic sclerosis: Is systemic sclerosis a Th17 disease?. Journal of Dermatological Science, 2008, 50, 240-242.	1.9	110
337	Serum BAFF and APRIL levels in patients with alopecia areata. Journal of Dermatological Science, 2008, 50, 236-239.	1.9	14
338	Autoantibodies against matrix metalloproteinase-1 in patients with localized scleroderma. Journal of Dermatological Science, 2008, 52, 47-54.	1.9	38
339	A Regulatory B Cell Subset with a Unique CD1dhiCD5+ Phenotype Controls T Cell-Dependent Inflammatory Responses. Immunity, 2008, 28, 639-650.	14.3	1,127
340	Association of IL-10 receptor 2 (IL10RB) SNP with systemic sclerosis. Biochemical and Biophysical Research Communications, 2008, 373, 403-407.	2.1	35
341	Elevated Serum Insulin-like Growth Factor (IGF-1) and IGF Binding Protein-3 Levels in Patients with Systemic Sclerosis: Possible Role in Development of Fibrosis. Journal of Rheumatology, 2008, 35, 2363-2371.	2.0	60
342	CD19 Regulates Skin and Lung Fibrosis via Toll-Like Receptor Signaling in a Model of Bleomycin-Induced Scleroderma. American Journal of Pathology, 2008, 172, 1650-1663.	3.8	192

#	Article	IF	CITATIONS
343	Novel Binding Site for Src Homology 2-containing Protein-tyrosine Phosphatase-1 in CD22 Activated by B Lymphocyte Stimulation with Antigen. Journal of Biological Chemistry, 2008, 283, 1653-1659.	3.4	12
344	A Case of Acute Cutaneous Graft-versus-Host Disease Mimicking Psoriasis Vulgaris. Dermatology, 2008, 216, 64-67.	2.1	26
345	Increased Serum Soluble OX40 in Patients with Systemic Sclerosis. Journal of Rheumatology, 2008, 35, 2359-2362.	2.0	68
346	Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. Journal of Clinical Investigation, 2008, 118, 3420-30.	8.2	762
347	A Case of Dermatomyositis Associated with Mechanic's Hand. Nishinihon Journal of Dermatology, 2008, 70, 606-609.	0.0	1
348	Clinical significance of serum hyaluronan levels in systemic sclerosis: association with disease severity. Journal of Rheumatology, 2008, 35, 1825-9.	2.0	25
349	CD83 Expression Is a Sensitive Marker of Activation Required for B Cell and CD4+ T Cell Longevity In Vivo. Journal of Immunology, 2007, 179, 4550-4562.	0.8	79
350	CD83 influences cell-surface MHC class II expression on B cells and other antigen-presenting cells. International Immunology, 2007, 19, 977-992.	4.0	50
351	Endothelial selectins regulate skin wound healing in cooperation with L-selectin and ICAM-1. Journal of Leukocyte Biology, 2007, 82, 519-531.	3.3	39
352	Intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 cooperatively contribute to the cutaneous Arthus reaction. Journal of Leukocyte Biology, 2007, 81, 1197-1204.	3.3	16
353	Intercellular Adhesion Molecule-1 Deficiency Attenuates the Development of Skin Fibrosis in Tight-Skin Mice. Journal of Immunology, 2007, 179, 698-707.	0.8	35
354	The involvement of Gab1 and PI 3-kinase in \hat{l}^21 integrin signaling in keratinocytes. Biochemical and Biophysical Research Communications, 2007, 361, 224-229.	2.1	6
355	Bullous pemphigoid positive for anti-BP180 and anti-laminin 5 antibodies in a patient with graft-vs-host disease. Journal of the American Academy of Dermatology, 2007, 56, S94-S97.	1.2	24
356	Phase-Dependent Roles of E-Selectin during Chronic Contact Hypersensitivity Responses. American Journal of Pathology, 2007, 170, 1649-1658.	3.8	12
357	CD19 Expression in B Cells Is Important for Suppression of Contact Hypersensitivity. American Journal of Pathology, 2007, 171, 560-570.	3.8	107
358	B cell signaling and autoimmune diseases: CD19/CD22 loop as a B cell signaling device to regulate the balance of autoimmunity. Journal of Dermatological Science, 2007, 46, 1-9.	1.9	43
359	BAFF Antagonist Attenuates the Development of Skin Fibrosis in Tight-Skin Mice. Journal of Investigative Dermatology, 2007, 127, 2772-2780.	0.7	69
360	Antigen specificity of antihistone antibodies in connective tissue disease patients with anti-U1RNP antibodies. Rheumatology International, 2007, 28, 113-119.	3.0	4

#	Article	IF	CITATIONS
361	Serum anti-FcÎ ³ receptor autoantibodies in patients with alopecia areata. Archives of Dermatological Research, 2007, 298, 493-498.	1.9	8
362	Recent Advances on Pathogenesis and Therapies in Systemic Sclerosis. Clinical Reviews in Allergy and Immunology, 2007, 33, 107-112.	6.5	17
363	Clinical evaluation of anti-aminoacyl tRNA synthetase antibodies in Japanese patients with dermatomyositis. Journal of Rheumatology, 2007, 34, 1012-8.	2.0	62
364	Inhibitory Role of CD19 in the Progression of Experimental Autoimmune Encephalomyelitis by Regulating Cytokine Response. American Journal of Pathology, 2006, 168, 812-821.	3.8	109
365	E- and P-Selectins Synergistically Inhibit Bleomycin-Induced Pulmonary Fibrosis. American Journal of Pathology, 2006, 169, 740-749.	3.8	14
366	B-Lymphocyte Depletion Reduces Skin Fibrosis and Autoimmunity in the Tight-Skin Mouse Model for Systemic Sclerosis. American Journal of Pathology, 2006, 169, 954-966.	3.8	195
367	Myocardial Damages in Systemic Sclerosis Detected by Gated Myocardial Perfusion SPECT and Sympathetic Imaging. Circulation Journal, 2006, 70, 1481-1487.	1.6	20
368	Activation of Akt by mechanical stretching in human epidermal keratinocytes. Experimental Dermatology, 2006, 15, 356-361.	2.9	33
369	Necrolytic migratory erythema without glucagonoma in a patient with short bowel syndrome. Journal of Dermatology, 2006, 33, 557-562.	1.2	16
370	Treatment of HIV-associated eosinophilic pustular folliculitis with narrow-band UVB. International Journal of Dermatology, 2006, 45, 1265-1267.	1.0	13
371	Heliotrope-like eruption mimicking dermatomyositis in a patient treated with imatinib mesylate for chronic myeloid leukemia. International Journal of Dermatology, 2006, 45, 1249-1251.	1.0	13
372	L-selectin and intercellular adhesion molecule-1 regulate the development of Concanavalin A-induced liver injury. Journal of Leukocyte Biology, 2006, 79, 696-705.	3.3	20
373	B Cell Antigen Receptor and CD40 Differentially Regulate CD22 Tyrosine Phosphorylation. Journal of Immunology, 2006, 176, 873-879.	0.8	30
374	The efficacy of self-administered stretching for finger joint motion in Japanese patients with systemic sclerosis. Journal of Rheumatology, 2006, 33, 1586-92.	2.0	43
375	B lymphocytes and systemic sclerosis. Current Opinion in Rheumatology, 2005, 17, 746-751.	4.3	53
376	Characterization and Localization of Side Population Cells in Mouse Skin. Stem Cells, 2005, 23, 834-841.	3.2	90
377	Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis. Molecular Immunology, 2005, 42, 821-831.	2.2	9
378	LEUKEMIA INHIBITORY FACTOR AS AN ANTI-APOPTOTIC MITOGEN FOR PLURIPOTENT MOUSE EMBRYONIC STEM CELLS IN A SERUM-FREE MEDIUM WITHOUT FEEDER CELLS. In Vitro Cellular and Developmental Biology - Animal, 2005, 41, 19.	1.5	59

#	Article	IF	CITATIONS
379	Pathogenesis of systemic sclerosis: Altered B cell function is the key linking systemic autoimmunity and tissue fibrosis. Journal of Dermatological Science, 2005, 39, 1-7.	1.9	84
380	Prevalence and clinical characteristics of anti-Mi-2 antibodies in Japanese patients with dermatomyositis. Journal of Dermatological Science, 2005, 40, 215-217.	1.9	51
381	Severely Impaired B Lymphocyte Proliferation, Survival, and Induction of the c-Myc:Cullin 1 Ubiquitin Ligase Pathway Resulting from CD22 Deficiency on the C57BL/6 Genetic Background. Journal of Immunology, 2004, 172, 2100-2110.	0.8	34
382	The CD19-CD21 Signal Transduction Complex of B Lymphocytes Regulates the Balance between Health and Autoimmune Disease: Systemic Sclerosis as a Model System. , 2004, 8, 55-90.		50
383	Dermatitis due to epiregulin deficiency and a critical role of epiregulin in immune-related responses of keratinocyte and macrophage. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 13921-13926.	7.1	71
384	Mechanical Stretching In Vitro Regulates Signal Transduction Pathways and Cellular Proliferation in Human Epidermal Keratinocytes. Journal of Investigative Dermatology, 2004, 122, 783-790.	0.7	143
385	CD22 regulates B lymphocyte function in vivo through both ligand-dependent and ligand-independent mechanisms. Nature Immunology, 2004, 5, 1078-1087.	14.5	166
386	Altered blood B lymphocyte homeostasis in systemic sclerosis: Expanded naive B cells and diminished but activated memory B cells. Arthritis and Rheumatism, 2004, 50, 1918-1927.	6.7	298
387	Association of a functionalCD19 polymorphism with susceptibility to systemic sclerosis. Arthritis and Rheumatism, 2004, 50, 4002-4007.	6.7	82
388	Characterization of multipotent adult stem cells from the skin: transforming growth factor-β (TGF-β) facilitates cell growth. Experimental Cell Research, 2004, 295, 194-203.	2.6	62
389	B Lymphocyte Signaling Established by the CD19/CD22 Loop Regulates Autoimmunity in the Tight-Skin Mouse. American Journal of Pathology, 2004, 165, 641-650.	3.8	84
390	Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis. Molecular Immunology, 2004, 41, 1123-1133.	2.2	123
391	Elevated circulating CD40L concentrations in patients with systemic sclerosis. Journal of Rheumatology, 2004, 31, 514-9.	2.0	37
392	Relation between hemodynamic changes after endoscopic transthoracic sympathicotomy and the number of sympathetic segments operated. Clinical Autonomic Research, 2003, 13, 1-1.	2.5	0
393	Function Blocking Autoantibodies Against Matrix Metalloproteinase-1 in Patients with Systemic Sclerosis. Journal of Investigative Dermatology, 2003, 120, 542-547.	0.7	86
394	Interleukin 15 induces the signals of epidermal proliferation through ERK and PI 3-kinase in a human epidermal keratinocyte cell line, HaCaT. Biochemical and Biophysical Research Communications, 2003, 301, 841-847.	2.1	48
395	CD19 regulates innate immunity by the toll-like receptor RP105 signaling in B lymphocytes. Blood, 2003, 102, 1374-1380.	1.4	117
396	Serum Levels of Tumor Necrosis Factor and Interleukin-13 Are Elevated in Patients with Localized Scleroderma. Dermatology, 2003, 207, 141-147.	2.1	72

#	Article	IF	CITATIONS
397	Serum concentrations of the CXC chemokines interleukin 8 and growth-regulated oncogene-alpha are elevated in patients with systemic sclerosis. Journal of Rheumatology, 2003, 30, 1524-8.	2.0	59
398	Complementary Roles for CD19 and Bruton's Tyrosine Kinase in B Lymphocyte Signal Transduction. Journal of Immunology, 2002, 168, 5465-5476.	0.8	40
399	Effects of Endoscopic Transthoracic Sympathicotomy on Hemodynamic and Neurohumoral Responses to Exercise in Humans Circulation Journal, 2002, 66, 357-361.	1.6	17
400	CD83 Expression Influences CD4+ T Cell Development in the Thymus. Cell, 2002, 108, 755-767.	28.9	188
401	CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. Journal of Clinical Investigation, 2002, 109, 1453-1462.	8.2	188
402	CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. Journal of Clinical Investigation, 2002, 109, 1453-1462.	8.2	93
403	B cell signal transduction and autoimmunity. Japanese Journal of Clinical Immunology, 2002, 25, 244-254.	0.0	0
404	Clinical significance of surfactant protein D as a serum marker for evaluating pulmonary fibrosis in patients with systemic sclerosis. Arthritis and Rheumatism, 2001, 44, 1363-1369.	6.7	92
405	A CD19-Dependent Signaling Pathway Regulates Autoimmunity in Lyn-Deficient Mice. Journal of Immunology, 2001, 167, 2469-2478.	0.8	56
406	CD19 Amplification of B Lymphocyte Ca2+ Responses. Journal of Biological Chemistry, 2001, 276, 44820-44827.	3.4	43
407	CD19 Can Regulate B Lymphocyte Signal Transduction Independent of Complement Activation. Journal of Immunology, 2001, 167, 3190-3200.	0.8	61
408	CD19 Regulates Intrinsic B Lymphocyte Signal Transduction and Activation Through a Novel Mechanism of Processive Amplification. Immunologic Research, 2000, 22, 281-298.	2.9	66
409	CD19 and CD22 Regulate a B Lymphocyte Signal Transduction Pathway That Contributes to Autoimmunity Keio Journal of Medicine, 2000, 49, 1-13.	1.1	47
410	The c-Abl Tyrosine Kinase Is Regulated Downstream of the B Cell Antigen Receptor and Interacts with CD19. Journal of Immunology, 2000, 165, 6872-6879.	0.8	64
411	Quantitative Genetic Variation in CD19 Expression Correlates with Autoimmunity. Journal of Immunology, 2000, 165, 6635-6643.	0.8	292
412	CD22 Forms a Quaternary Complex with SHIP, Grb2, and Shc. Journal of Biological Chemistry, 2000, 275, 17420-17427.	3.4	115
413	Serum levels of tissue inhibitor of metalloproteinases 2 in patients with systemic sclerosis. Journal of the American Academy of Dermatology, 2000, 42, 70-75.	1.2	38
414	CD19 Regulates Src Family Protein Tyrosine Kinase Activation in B Lymphocytes through Processive Amplification. Immunity, 2000, 13, 47-57.	14.3	189

Манави Гилиото

#	Article	IF	CITATIONS
415	Modulation of B Lymphocyte Antigen Receptor Signal Transduction by a CD19/CD22 Regulatory Loop. Immunity, 1999, 11, 191-200.	14.3	144
416	Serum concentrations of carboxyterminal propeptide of type 1 procollagen and tissue inhibitor of metalloproteinase 1 in patients with dermatomyositis. Archives of Dermatological Research, 1998, 290, 253-257.	1.9	10
417	Increased serum concentration of hyaluronate in dermatomyositis patients. Archives of Dermatological Research, 1998, 290, 579-581.	1.9	9
418	CD19 regulates B lymphocyte responses to transmembrane signals. Seminars in Immunology, 1998, 10, 267-277.	5.6	89
419	Antiâ€Ribosomal P Protein Antibodies in a Japanese Patient with Systemic Sclerosis. Journal of Dermatology, 1996, 23, 33-36.	1.2	0
420	Elevated soluble CD23 levels in the sera from patients with localized scleroderma. Archives of Dermatological Research, 1996, 288, 74-78.	1.9	19
421	Soluble CD4 and CD8 in serum from patients with localized scleroderma. Archives of Dermatological Research, 1996, 288, 358-362.	1.9	36
422	Connective Tissue Growth Factor Gene Expression in Tissue Sections From Localized Scleroderma, Keloid, and Other Fibrotic Skin Disorders. Journal of Investigative Dermatology, 1996, 106, 729-733.	0.7	402
423	Elevated soluble CD23 levels in the sera from patients with localized scleroderma. Archives of Dermatological Research, 1996, 288, 74-78.	1.9	2
424	Soluble CD4 and CD8 in serum from patients with localized scleroderma. Archives of Dermatological Research, 1996, 288, 358-362.	1.9	3
425	Autoantibodies to pyruvate dehydrogenase complex in patients with systemic sclerosis. Arthritis and Rheumatism, 1995, 38, 985-989.	6.7	23
426	Autoantibodies to the heat-shock protein hsp73 in localized scleroderma. Archives of Dermatological Research, 1995, 287, 581-585.	1.9	15
427	Serum tissue inhibitor of metalloproteinases in patients with systemic sclerosis. Journal of the American Academy of Dermatology, 1995, 33, 973-978.	1.2	65
428	Clinical characteristics associated with antihistone antibodies in patients with localized scleroderma. Journal of the American Academy of Dermatology, 1994, 31, 567-571.	1.2	68
429	Increased levels of circulating intercellular adhesion molecule-1 in patients with localized scleroderma. Journal of the American Academy of Dermatology, 1994, 31, 591-595.	1.2	40
430	Epidermal clearance of <i>Candida albicans</i> is mediated by IL-17 but independent of fungal innate immune receptors. International Immunology, 0, , .	4.0	3